Gilead Sciences 8-K: Officer & Director Changes

Ticker: GILD · Form: 8-K · Filed: 2025-08-14T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

Related Tickers: GILD

TL;DR

Gilead 8-K filed: board/exec changes reported.

AI Summary

Gilead Sciences, Inc. filed an 8-K on August 14, 2025, reporting events as of August 10, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.

Why It Matters

Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: low — This filing is procedural, reporting standard corporate governance events without immediate financial implications.

Key Players & Entities

FAQ

What specific officer or director positions were affected by the events reported on August 10, 2025?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and positions are not detailed in this excerpt.

Were there any new directors elected to the Gilead Sciences board?

Yes, the filing explicitly lists 'Election of Directors' as an item covered, indicating new directors may have been appointed.

What type of compensatory arrangements were made for certain officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' but does not provide specific details about the nature or value of these arrangements in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on August 10, 2025.

What is the principal business address of Gilead Sciences, Inc.?

The principal executive offices are located at 333 Lakeside Drive, Foster City, California 94404.

From the Filing

0000882095-25-000035.txt : 20250814 0000882095-25-000035.hdr.sgml : 20250814 20250814160822 ACCESSION NUMBER: 0000882095-25-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250810 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250814 DATE AS OF CHANGE: 20250814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 251218957 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20250810.htm FORM 8-K gild-20250810 0000882095 false 0000882095 2025-08-10 2025-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 10, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2025, the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the “Company”), appointed Erin Burkhart as Senior Vice President, Controllership and principal accounting officer of the Company, effective as of September 22, 2025 (the “Transition Date”). Ms. Burkhart, age 46, has served as Group Vice President and Chief Accounting Officer of BioMarin Pharmaceutical Inc., a biotechnology company, since May 2022.

View on Read The Filing